This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretio ...

Reduction seen in risk for readmission, wound dehiscence, and hematoma, but no significant differences seen in rates of infection, bleeding ...

Lexaria Bioscience (LEXX) announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...